American Association for Cancer Research

SHERPA: Unknown

People

  1. Traina
    Traina
  2. Hudis
    Hudis
  3. Patil
    Patil
  4. Gucalp
    Gucalp
  5. Lake
    Lake
  6. Norton
    Norton
  7. Modi
    Modi
  8. Dang
    Dang
  9. Dickler
    Dickler
  10. Moynahan
    Moynahan

Groups

  1. Breast Medicine Service (54)
  2. Department of Medicine (54)
  3. Solid Tumor Oncology Division (54)
  4. Survivorship Research (54)
  5. Epidemiology and Biostatistics (21)
  6. Biostatistics Service (19)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  8. GSK Faculty (11)
  9. Department of Pathology and Laboratory Medicine (10)
  10. Population Sciences Research Program (9)
Search Within
  1. "Tiffany Traina"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (10)
Groups
  1. Breast Medicine Service (54)
  2. Department of Medicine (54)
  3. Solid Tumor Oncology Division (54)
  4. Survivorship Research (54)
  5. Epidemiology and Biostatistics (21)
  6. Biostatistics Service (19)

More Groups

People
  1. Tiffany Traina (54)
  2. Clifford Hudis (28)
  3. Sujata Patil (19)
  4. Ayca Gucalp (18)
  5. Larry Norton (12)
  6. Diana Lake (9)

More People

Years
  1. 2022 (2)
  2. 2021 (5)
  3. 2020 (5)
  4. 2018 (4)
  5. 2017 (3)
  6. 2016 (6)

More Years

Publications
  1. Cancer Research (44)
  2. Clinical Cancer Research (10)

Results (54)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease
    Meeting Abstract

    Krop, I.; Masuda, N.; Kogawa, T.; Takahashi, S.; Yonemori, K.; Inoue, K.; Nakayama, T.; Yamamoto, Y.; Alvarez, R.; Toyama, T.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Genomic profiling of primary and metastatic breast cancer in men
    Meeting Abstract

    Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer
    Meeting Abstract

    Krop, I.; Abramson, V.; Colleoni, M.; Traina, T.; Holmes, F.; Estevez, L.; Hart, L.; Awada, A.; Zamagni, C.; Morris, P.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)
    Meeting Abstract

    Gucalp, A.; Edelweiss, M.; Patil, S.; Gounder, M. M.; Feigin, K. N.; Corben, A.; Arumov, A.; Traina, T. A.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor
    Meeting Abstract

    Elias, A.; Gucalp, A.; Bardia, A.; Resaul, A.; Eisner, J.; Baskin-Bey, E.; Traina, T. A.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC)
    Meeting Abstract

    Dent, R.; Tan, T.; Kim, S. B.; Traina, T.; McArthur, H.; Im, Y. H.; Creel, T.; Blackwell, K.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • A phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer
    Journal Article

    Schwartzberg, L. S.; Yardley, D. A.; Elias, A. D.; Patel, M.; LoRusso, P.; Burris, H. A.; Gucalp, A.; Peterson, A. C.; Blaney, M. E.; Steinberg, J. L.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer
    Meeting Abstract

    Dent, R.; Schmid, P.; Cortes, J.; Kim, S. B.; Andre, F.; Abramson, V.; Cardoso, F.; Colleoni, M.; Morris, P.; Steinberg, J.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer
    Meeting Abstract

    Elias, A. D.; Burris, H. A.; Patel, M. R.; Schwartzberg, L. S.; Richer, J. K.; Kavalerchik, E.; Stopatschinskaja, S.; Gibbons, J.; Markova, D.; Steinberg, J. L.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: